B 669: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 155807 |
| CHEMBL ID | 151462 |
| SCHEMBL ID | 3750119 |
| MeSH ID | M0096244 |
| Synonym |
|---|
| 3-(cyclohexylimino)-3,5-dihydro-n,5-diphenyl-2-phenazinamine |
| 78182-92-0 |
| b 669 |
| (3e)-3-cyclohexylimino-n,5-diphenyl-phenazin-2-amine |
| CHEMBL151462 |
| 3-cyclohexylimino-n,5-diphenylphenazin-2-amine |
| SCHEMBL3750119 |
| b-669 |
| b669 |
| 2-phenazinamine, 3-(cyclohexylimino)-3,5-dihydro-n,5-diphenyl- |
| HY-119929 |
| CS-0078792 |
| AKOS040747907 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID144313 | Concentration for 100% inhibition of growth of dapsone sensitive Mycobacterium smegmatis 607 strain in vitro | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | Clofazimine analogues active against a clofazimine-resistant organism. |
| AID144314 | 100% inhibition of growth of rifampicin resistant Mycobacterium smegmatis 607 strain in vitro | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | Clofazimine analogues active against a clofazimine-resistant organism. |
| AID144311 | 100% inhibition of growth of clofazimine resistant Mycobacterium smegmatis 607 strain in vitro | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | Clofazimine analogues active against a clofazimine-resistant organism. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (12.50) | 18.7374 |
| 1990's | 14 (87.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Article | Year |
|---|---|
| Augmentative inhibition of lymphocyte proliferation by cyclosporin A combined with the riminophenazine compounds clofazimine and B669. Inflammation research : official journal of the European Histamine Research Society ... [et al.], Volume: 44, Issue: 9 | 1995 |
| [information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | |